2023
Disparities in stage at diagnosis for liver cancer in China
Shan T, Ran X, Li H, Feng G, Zhang S, Zhang X, Zhang L, Lu L, An L, Fu R, Sun K, Wang S, Chen R, Li L, Chen W, Wei W, Zeng H, He J. Disparities in stage at diagnosis for liver cancer in China. Journal Of The National Cancer Center 2023, 3: 7-13. PMID: 39036312, PMCID: PMC11256694, DOI: 10.1016/j.jncc.2022.12.002.Peer-Reviewed Original ResearchLiver cancerStage IIIStage distributionHospital-based studyProportion of patientsLiver Cancer stagePrimary liver cancerCancer control policiesCancer awarenessCancer stageTreatment strategiesFamily historyStudy populationStage ISocioeconomic populationsCancerLogistic regressionPatientsDiagnosisEarly detectionHigher proportionDifferent populationsPopulationProportionHospital
2021
Tiliroside as a CAXII inhibitor suppresses liver cancer development and modulates E2Fs/Caspase-3 axis
Han R, Yang H, Lu L, Lin L. Tiliroside as a CAXII inhibitor suppresses liver cancer development and modulates E2Fs/Caspase-3 axis. Scientific Reports 2021, 11: 8626. PMID: 33883691, PMCID: PMC8060393, DOI: 10.1038/s41598-021-88133-7.Peer-Reviewed Original ResearchConceptsLiver cancer developmentLiver cancerCancer developmentLiver cancer cell linesCD133 expression levelsAnti-proliferation effectQuantitative reverse transcription PCRCancer cell linesCancer deathTHLE-3THLE-3 cellsAlternative therapiesReverse transcription-PCREffective therapyFatal causeNC groupTherapeutic implicationsInvasion assaysTherapeutic useClinic practiceELISA kitHigher anti-proliferation effectColony formationTranscription-PCRAnticancer efficacy